Evaluation of Study Experiences of Neuroendocrine Tumor Patients
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT05967481
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This research will admit a wide range of data on the clinical study experience of neuroendocrine tumor patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with neuroendocrine tumor.
Key Dates
- Start date
- Aug 31, 2024
- Status verified
- Jul 2023
- Primary completion
- Aug 31, 2025
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Rate of patients who decide to join in a neuroendocrine tumor clinical research [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill4159004227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 |
Find similar trials in San Francisco, CA
Related Studies
- Dose-defining Study of Tirapazamine Combined With Embolization in Liver CancerPHASE1/PHASE2 · Recruiting · Teclison Ltd. · Palo Alto, California
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsPHASE1 · Recruiting · Anusha Kalbasi · Duarte, California
- CapTemY90 for Grade 2/3 NET Liver MetastasesPHASE2 · Recruiting · Abramson Cancer Center at Penn Medicine · La Jolla, California